Computational Drug Repurposing for All EBS Cases


I'm Interested

Trial ID: NCT03269474


The study will compare gene expression differences between blistered and non-blistered skin from individuals with all subtypes of EB, as well as normal skin from non-EB subjects. State of the art computational analysis will be performed to help identify new drugs that might help all EB wound healing and reduce pain. Researchers will focus on drugs that have already been approved for treatment of other dermatologic or non-dermatologic diseases, and therefore be repurposed for treatment of EB. Drug development is a very expensive process taking decades for execution. Drug repurposing on the other hand, significantly reduces the cost and shortens the amount of time that is needed to bring effective treatments to clinical use. To date, there is no specific treatment targeting the physiology and immunologic response in EB patients during wound healing. Market availability of repurposed medications will provide all EB patients rapid access to treatments, thus improving their quality of life.

Official Title

Computational Drug Repurposing for All Epidermolysis Bullosa Simplex (EBS) Cases

Stanford Investigator(s)

Joyce Teng, MD, PhD
Joyce Teng, MD, PhD

Professor of Dermatology and, by courtesy, of Pediatrics

Kavita Sarin, MD, PhD
Kavita Sarin, MD, PhD

Associate Professor of Dermatology


Inclusion Criteria:

* Subjects of all ages
* Diagnosis of all subtypes of EB subjects
* Healthy, non-EB subjects
* Ability to complete study visit to collect tissue and blood specimen

Exclusion Criteria:

* Pregnancy, breast feeding
* Prior history of liver disease
* Serious known concurrent medical illness or infection, which could potentially present a safety risk and/or prevent tissue collection from subjects


procedure: Experimental Group


I'm Interested

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305
Karima Belhocine